Target

B7-H3

CD276 antigen

Also: CD276

49open trials
57trials in total
117publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276
1 Jun 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
31 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Hannibal ante portas: B7-H3-directed therapies at the gates of precision oncology.
4 Nov 2026· Biomolecules & biomedicine· PUBMED
Publication
Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3-Directed and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer.
3 Nov 2026· Molecular cancer therapeutics· PUBMED
Publication
Anti-B7-H3 ADCs Take Center Stage against SCLC at WCLC.
2 Nov 2026· Cancer discovery· PUBMED
Publication
TARBP2 facilitates renal cell carcinoma immune escape by suppressing 53BP1 phase separation to upregulate B7-H3.
2 Nov 2026· The Journal of clinical investigation· PUBMED
Trial
SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
1 Nov 2026· PHASE1 · RECRUITING· CTGOV
Publication
Stromal B7-H3 Expression Characterizes an Immune-Hot Microenvironment and Predicts Response to PD-1 Blockade in Gastric Cancer.
23 Oct 2026· Laboratory investigation; a journal of technical methods and pathology· PUBMED
Trial
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
16 Oct 2026· PHASE1 · RECRUITING· CTGOV
Publication
Prognostic Significance of B7-H3, TROP2, and p16 Expression in Pleural Mesothelioma: Clinicopathological Correlations and Survival Outcomes.
15 Oct 2026· Journal of clinical medicine· PUBMED
Publication
Locoregionally delivered PD-1 blockade augments B7-H3 targeting CAR T cell efficacy in models of glioblastoma.
13 Oct 2026· JCI insight· PUBMED
Publication
Stimulator of Interferon Genes (STING) Agonist-Loaded Copper-Based Nanoparticles for B7-H3 Blockade-Enhanced Chemodynamic-Immunotherapy of Ovarian Cancer.
10 Oct 2026· International journal of nanomedicine· PUBMED
Publication
Clinical and therapeutic relevance of B7-H3 in sarcomas: molecular insights from a systematic review.
8 Oct 2026· Journal of drug targeting· PUBMED
Publication
Preclinical Evaluation of B7-H3-Targeted ADC-Based Molecular Imaging in Lung and Triple-Negative Breast Cancer.
5 Oct 2026· Molecular pharmaceutics· PUBMED
Publication
Induced pluripotent stem cell-derived natural killer cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engager.
1 Oct 2026· Neuro-oncology· PUBMED
Publication
Intrathecal Allogeneic B7-H3-Targeted CAR γδ T Cells for Leptomeningeal Metastasis from Solid Tumors: Safety, Efficacy, and Immunologic Dynamics in a Phase I Trial.
1 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
FXR1 Promotes Esophageal Squamous Cell Carcinoma via JAK2/STAT3/B7-H3 Pathway.
1 Oct 2026· Anticancer research· PUBMED
Publication
Drug discovery strategies targeting B7-H3 (CD276) in lung and gastric cancers: From biological validation to next-generation small molecules, biologics and cell-based immunotherapies.
23 Sept 2026· Drug discovery today· PUBMED
Preprint
Low-dose radiopharmaceutical therapy enhances the efficacy of B7-H3 CAR T cells in murine metastatic neuroblastoma.
22 Sept 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Correction: B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.
19 Sept 2026· Journal of experimental & clinical cancer research : CR· PUBMED
Publication
Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.
18 Sept 2026· Cancer discovery· PUBMED
Trial
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
4 Sept 2026· PHASE2 · RECRUITING· CTGOV
Publication
Immune Checkpoint B7-H3 Inhibition Reprograms Acute Neuroinflammation and Protects the Brain After Acute Ischemic Stroke.
3 Sept 2026· Stroke· PUBMED
Trial
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
1 Sept 2026· PHASE3 · RECRUITING· CTGOV
Trial
B7-H3.CD28Z.CART in CNS Neoplasms
1 Sept 2026· PHASE1 · RECRUITING· CTGOV
Publication
Autocrine Control of CD276 by SPARC in Liver Cancer and Its Contribution to Immune Escape and Resistance to Immunotherapy: Elucidating How SPARC Shapes the Tumor Microenvironment and Undermines the Response to Immune Checkpoint Inhibition.
1 Sept 2026· Journal of biochemical and molecular toxicology· PUBMED
Publication
CD276 promotes lipid metabolic reprogramming and regulates ferroptosis in clear cell renal cell carcinoma by upregulating FASN expression via SREBP1.
31 Aug 2026· Human cell· PUBMED
Publication
Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.
25 Aug 2026· Cell reports. Medicine· PUBMED
Trial
B7-H3.CD28Z.CART in Solid Tumors
24 Aug 2026· PHASE1 · RECRUITING· CTGOV

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error